Eden Issues 14.17 Million Shares to Finalise $4 Million Raise

Final Tranche Closes $4 Million Placement

Eden Innovations Ltd (ASX:EDE) has completed the second and final tranche of its $4 million institutional placement, issuing 14,166,666 fully paid ordinary shares at an issue price of $0.18 per share. This tranche raised approximately $2.55 million before costs, bringing the total placement proceeds to $4 million as initially announced on 17 April 2026.

The shares issued in this tranche rank equally with existing shares, ensuring no dilution of rights for current shareholders beyond the increase in share count. The issuance utilised the company’s placement capacities under ASX Listing Rules 7.1A and 7.1, with 13,888,888 shares issued under the former and 277,778 shares under the latter.

Regulatory Compliance and Cleansing Notice

Alongside the placement completion, Eden Innovations provided a cleansing notice under section 708A of the Corporations Act 2001 (Cth). The notice confirms that the shares were issued without disclosure under Part 6D.2 of the Act and that the company has complied with all relevant disclosure obligations, including Chapter 2M and section 674 of the Act. Importantly, the company stated there is no excluded information that would require disclosure to the market.

This procedural step is standard for placements of this nature but reassures investors that the company remains compliant with continuous disclosure and market integrity requirements.

Capital Raise Context and Strategic Positioning

The $4 million placement forms a critical part of Eden’s recent capital strategy, which has included eliminating costly debt and accelerating expansion in the US market, particularly through its EdenCrete and EdenShield divisions. EdenShield, launched earlier this year, targets defence and critical infrastructure sectors with advanced carbon nanotube-enhanced materials and dual-fuel systems, positioning Eden to tap into a growing global aerospace and defence market.

This capital raise supports these growth initiatives, although the company has not detailed the specific allocation of proceeds from the placement. Market participants will be watching for updates on how this fresh capital is deployed amid Eden’s ongoing expansion and product commercialisation efforts.